Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial

Brogan, Paul; Arch, Barbara; Hickey, Helen; Anton, Jordi; Iglesias, Este; Baildam, Eileen; Mahmood, Kamran; Cleary, Gavin; Moraitis, Elena; Papadopoulou, Charalampia; Beresford, Michael; Riley, Phil; Demir, SELCAN; Ozen, Seza; Culeddu, Giovanna; Hughes, Dyfrig; Dolezalova, Pavla; Hampson, Lisa; Whitehead, John; Jayne, David; Ruperto, Nicola; Eleftheriou, Despina

doi:10.1002/art.41730

Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial

Atıf İçin Kopyala

Brogan P. A., Arch B., Hickey H., Anton J., Iglesias E., Baildam E., ...Daha Fazla

ARTHRITIS & RHEUMATOLOGY, cilt.73, sa.9, ss.1673-1682, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 73 Sayı: 9
Basım Tarihi: 2021
Doi Numarası: 10.1002/art.41730
Dergi Adı: ARTHRITIS & RHEUMATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.1673-1682
Eskişehir Osmangazi Üniversitesi Adresli: Hayır

Özet

Objective. Cyclophosphamide (CYC) is used in clinical practice off-label for the induction of remission in childhood polyarteritis nodosa (PAN). Mycophenolate mofetil (MMF) might offer a less toxic alternative. This study was undertaken to explore the relative effectiveness of CYC and MMF treatment in a randomized controlled trial (RCT).